mirage

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Ruilope Urioste, Luis Miguel
dc.contributor.author Agarwal, Rajiv L.
dc.contributor.author Anker, Stefan D.
dc.contributor.author Bakris, George
dc.contributor.author Filippatos, Gerasimos S.
dc.contributor.author Nowack, Christina
dc.contributor.author Kolkhof, Peter
dc.contributor.author Joseph, A.
dc.contributor.author Mentenich, N.
dc.contributor.author FIGARO-DKD study investigators
dc.contributor.author Et al.
dc.date.accessioned 2020-01-30T19:24:25Z
dc.date.available 2020-01-30T19:24:25Z
dc.date.issued 2019
dc.identifier.citation Ruilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., … FIGARO-DKD study investigators. (2019). Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American Journal of Nephrology, 50(5), 345–356. https://doi.org/10.1159/000503712 spa
dc.identifier.issn 0250-8095
dc.identifier.issn 1421-9670
dc.identifier.uri http://hdl.handle.net/11268/8560
dc.description.abstract Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m2 and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049. spa
dc.description.sponsorship Sin financiación spa
dc.language.iso eng spa
dc.title Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial spa
dc.type article spa
dc.description.impact 3.411 JCR (2019) Q1, 18/85 Urology & Nephrology spa
dc.description.impact 1.330 SJR (2019) Q1, 9/66 Nephrology spa
dc.description.impact No data IDR 2019 spa
dc.identifier.doi 10.1159/000503712
dc.rights.accessRights openAccess spa
dc.subject.uem Aparato circulatorio spa
dc.subject.uem Diabetes spa
dc.subject.unesco Sistema cardiovascular spa
dc.subject.unesco Enfermedad cardiovascular spa
dc.subject.unesco Azúcar
dc.description.filiation UEM spa
dc.relation.publisherversion https://doi.org/10.1159/000503712 spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record